Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123156 | 0.90 | ESR2 (0.57) | GPR119ESR2NR1H2EGLN2NPC1 | |
| SCHEMBL6324611 | 0.86 | GPR119 (0.46) | GPR119ESR2NR1H2EGLN2NPC1 | |
| SCHEMBL5661604 | 0.85 | ESR2 (0.50) | GPR119ESR2NR1H2EGLN2NPC1 | |
| SCHEMBL5467960 | 0.85 | ESR2 (0.68) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL30548176 | 0.83 | ESR2 (0.69) | GPR119ESR2NR1H2DRD2DRD3 | |
| SCHEMBL5453239 | 0.83 | ESR2 (0.55) | GPR119ESR2NR1H2NPC1RAB9A | |
| SCHEMBL451998 | 0.83 | ESR2 (0.69) | GPR119ESR2NR1H2DRD2DRD3 | |
| SCHEMBL2416879 | 0.83 | NR1H2 (0.67) | GPR119ESR2NR1H2DRD2DRD3 | |
| SCHEMBL29586616 | 0.83 | NR1H2 (0.67) | GPR119ESR2NR1H2DRD2DRD3 | |
| SCHEMBL3695530 | 0.80 | ESR2 (0.61) | GPR119ESR2NR1H2EGLN2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | GPR119 1092/4885ESR2 573/4885NR1H2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.